Rivian and Lucid both disappointed early investors. Both companies face supply chain issues and intense competition. But one ...

Wall Street veteran Jim Cramer is doubting the deal's long-term potential. Rivian may be a better buy due to a deal with VW.

Lucid still has a long road ahead, but it is navigating a clear path as it works toward being sustainably profitable.

Lucid Diagnostics' EsoGuard test may soon gain Medicare coverage, boosting its market potential. Read more here.

On that note, earnings season is upon us and two stood out to me: GM and Tesla. Both companies are facing pressure from ...

CarMax reports on the dilemma of buying an EV now versus waiting for better technology, advising consumers to define their ...

US Dollar South African Rand, Nasdaq 100, S&P 500, Intel Corporation. Read 's Market Analysis on Investing.com ZA.